New drugs in the treatment of psoriasis

Expert Opinion on Investigational Drugs

Volumn 9, Issue 1, 2000, Pages 79-93

  DiSepio, D ^a   Chandraratna, R A S ^a  

^a ALLERGAN INC   (United States)

Author keywords

Immunosuppressive; Immunotherapy; Psoriasis; Retinoid; Therapy; Vitamin D

Indexed keywords

A 86281; CLOBETASOL PROPIONATE; COAL TAR; COLECALCIFEROL DERIVATIVE; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENILEUKIN DIFTITOX; DITHRANOL; EMOLLIENT AGENT; ENZYME INHIBITOR; HU 1124; INOSINATE DEHYDROGENASE INHIBITOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MONOCLONAL ANTIBODY; OKTCDR4A; PIMECROLIMUS; RETINOL DERIVATIVE; SDZ 281 240; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOIMMUNE DISEASE; CHILL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; FEVER; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERTENSION; IMMUNOMODULATION; NEPHROTOXICITY; NEUROTOXICITY; PSORIASIS; RECURRENT DISEASE; REVIEW;

EID: 0033988640     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.1.79     Document Type: Review

References (117)